Microvascular resistance of the culprit coronary artery in acute ST-elevation myocardial infarction by Carrick, David et al.
1insight.jci.org   doi:10.1172/jci.insight.85768
c l i n i c a l  m e d i c i n e
Authorship note: D. Carrick and C. 
Haig contributed equally to this work.
Conflict of interest: C. Berry has acted 
as a consultant to St. Jude Medical, a 
manufacturer of the diagnostic coronary 
guide wires used in this study. K.G. 
Oldroyd has acted as a consultant to St. 
Jude Medical and Volcano Corporation. 
These companies had no involvement in 
this research.
Submitted: December 1, 2015 
Accepted: March 29, 2016 
Published: May 5, 2016
Reference information: 
JCI Insight. 2016;1(6):e85768. 
doi:10.1172/jci.insight.85768.
Microvascular resistance of the culprit 
coronary artery in acute ST-elevation 
myocardial infarction
David Carrick,1,2 Caroline Haig,3 Jaclyn Carberry,1,2 Vannesa Teng Yue May,1,2 Peter McCartney,1,2  
Paul Welsh,1 Nadeem Ahmed,1 Margaret McEntegart,2 Mark C. Petrie,1,2 Hany Eteiba,2  
Mitchell Lindsay,2 Stuart Hood,2 Stuart Watkins,2 Ahmed Mahrous,2 Samuli M.O. Rauhalammi,2  
Ify Mordi,1 Ian Ford,3 Aleksandra Radjenovic,1 Naveed Sattar,1 Keith G. Oldroyd,2 and Colin Berry1,2
1BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 
Glasgow, United Kingdom. 2West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank,  
United Kingdom. 3Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom.
Introduction
Acute ST-elevation myocardial infarction (STEMI) is a major cause of  premature death and heart failure 
acutely and in the longer term (1, 2). Primary percutaneous coronary intervention (PCI), the evidence-
based standard of  care (1, 3), aims to rapidly restore blood flow in the culprit coronary artery by balloon 
angioplasty followed by stent implantation. The success of  this intervention, defined as normal or near nor-
mal coronary blood flow, as indicated by thrombolysis in myocardial infarction (TIMI) flow grades 2 and 
3, typically occurs in ≥90% of  patients (4, 5). Despite routine successful coronary reperfusion, a failure of  
BACKGROUND. Failed myocardial reperfusion is common and prognostically important after acute 
ST-elevation myocardial infarction (STEMI). The purpose of this study was to investigate coronary 
flow reserve (CFR), a measure of vasodilator capacity, and the index of microvascular resistance 
(IMR; mmHg × s) in the culprit artery of STEMI survivors.
METHODS. IMR (n = 288) and CFR (n = 283; mean age [SD], 60 [12] years) were measured acutely 
using guide wire–based thermodilution. Cardiac MRI disclosed left ventricular pathology, function, 
and volumes at 2 days (n = 281) and 6 months after STEMI (n = 264). All-cause death or first heart 
failure hospitalization was independently adjudicated (median follow-up 845 days).
RESULTS. Myocardial hemorrhage and microvascular obstruction occurred in 89 (42%) and 114 (54%) 
patients with evaluable T2*-MRI maps. IMR and CFR were associated with microvascular pathology 
(none vs. microvascular obstruction only vs. microvascular obstruction and myocardial hemorrhage) 
(median [interquartile range], IMR: 17 [12.0–33.0] vs. 17 [13.0–39.0] vs. 37 [21.0–63.0], P < 0.001; 
CFR: 1.7 [1.4–2.5] vs. 1.5 [1.1–1.8] vs. 1.4 [1.0–1.8], P < 0.001), whereas thrombolysis in myocardial 
infarction blush grade was not. IMR was a multivariable associate of changes in left ventricular 
end-diastolic volume (regression coefficient [95% CI] 0.13 [0.01, 0.24]; P = 0.036), whereas CFR 
was not (P = 0.160). IMR (5 units) was a multivariable associate of all-cause death or heart failure 
hospitalization (n = 30 events; hazard ratio [95% CI], 1.09 [1.04, 1.14]; P < 0.001), whereas CFR (P = 
0.124) and thrombolysis in myocardial infarction blush grade (P = 0.613) were not. IMR had similar 
prognostic value for these outcomes as <50% ST-segment resolution on the ECG.
CONCLUSIONS. IMR is more closely associated with microvascular pathology, left ventricular 
remodeling, and health outcomes than the angiogram or CFR.
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myocardial reperfusion, manifesting initially as microvascular obstruction within the infarct core and sub-
sequently by vascular degradation and hemorrhagic transformation (6), typically affects half  of  all patients 
with acute STEMI and is an adverse prognostic complication (7–9).
The improved early survival rates following acute STEMI in the past decade have been associated with 
a persistently high incidence of  heart failure in the long term (10). One explanation for this conundrum 
is that more people are surviving the incident STEMI event, but with injured hearts that increase the risk 
of  future heart failure. Specifically, the failure to reperfuse the myocardium, and the related pathologic 
sequelae of  microvascular obstruction and myocardial hemorrhage, are causally implicated in the develop-
ment of  adverse left ventricular (LV) remodeling, heart failure, and death (5, 11–13).
Cardiac MRI is the reference diagnostic test for detection of  microvascular pathology; however, MRI 
is not routinely performed in clinical practice (1, 3). The ECG is the standard-of-care test for failed myo-
cardial reperfusion (1); however, the surface ECG has limited sensitivity for microvascular obstruction 
(14). The TIMI myocardial perfusion grade is an angiographic method to describe the filling and clearance 
of  radiographic contrast in the myocardium, but it is mainly used for research (15, 16). Accordingly, an 
invasive diagnostic test that could be routinely used to assess for failed myocardial reperfusion (that is com-
monly missed) would potentially represent a practice advance.
Coronary guide wire–based sensor technologies have emerged as new diagnostic tools for the invasive 
management of  coronary artery disease (3). Coronary flow reserve (CFR) reflects epicardial and micro-
vascular vasodilator capacity (17, 18). The index of  microvascular resistance (IMR) is a direct measure of  
coronary microvascular resistance. IMR is the product of  distal coronary pressure and the mean transit 
time(s) of  a 3 ml intracoronary bolus of  saline, manually administered at room temperature, during hyper-
emia, achieved with i.v. adenosine (140 μg/kg/min) (19). IMR has superior reproducibility and less hemo-
dynamic dependence than CFR (20) but is not independent of  LV mass, unlike CFR (21).
The comparative pathophysiological and prognostic significance of  IMR and CFR in patients 
with acute STEMI is incompletely understood (22–24). Since IMR and CFR reflect microvascular 
resistance and vascular reactivity, respectively, their associations with microvascular pathology with-
in the infarct zone, as revealed noninvasively by MRI, and systemic immune activation, as revealed 
by circulating concentrations of  the cytokine IL-6 (25, 26) and C-reactive protein (CRP), may differ. 
IMR and CFR may not be interchangeable, but instead each metric may reflect different states of  
acute vascular injury (27).
We aimed to measure IMR and CFR in the culprit coronary artery immediately after emergency PCI in 
a large, relatively unselected population of  patients with acute STEMI enrolled during daily practice. The 
specific aims were to assess (a) the feasibility of  routine guide wire–based assessments of  microvascular 
function during routine care; (b) the relationships of  IMR and CFR with infarct pathologies, including 
myocardial hemorrhage and microvascular obstruction, revealed by cardiac MRI; (c) the relationships of  
IMR and CFR with circulating concentrations of  IL-6; and (d) the prognostic relationships of  IMR and 
CFR with prespecified LV surrogate outcomes, as revealed by MRI and N-terminal pro b-type natriuretic 
peptide (NT-proBNP) concentration at 6 months and all-cause death and heart failure hospitalization and 
major adverse cardiac events (MACE) in the longer term.
We hypothesized that (a) CFR would be more closely associated with microvascular obstruction, 
a potentially reversible pathology, whereas IMR would be more closely associated with irreversible 
microvascular damage, as revealed by myocardial hemorrhage; (b) IMR and CFR would be more 
closely associated with microvascular pathology, as revealed by MRI, than established measures of  
failed myocardial reperfusion, including the duration of  ischaemia, the persistent ST-segment eleva-
tion on the surface ECG, and angiographic parameters; and (c) IMR has greatest prognostic signifi-
cance based on its association with irreversible vascular damage, surrogate outcomes, and all-cause 
death and heart failure.
Statistics. Categorical variables are expressed as number and percentage of  patients. Most continuous 
variables followed a normal distribution and are therefore presented as means together with SD. Those vari-
ables that did not follow a normal distribution are presented as medians with interquartile range (IQR). Dif-
ferences between independent groups were assessed using 1-way ANOVA, Kruskal-Wallis tests, or Fisher’s 
tests where appropriate. Univariable and multivariable logistic regression analyses were performed to iden-
tify predictors of  intramyocardial hemorrhage and microvascular obstruction. Models were compared using 
Harrel’s C-statistic. Kaplan-Meier and Cox proportional hazards methods were used to identify potential 
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Table 1. Clinical and angiographic characteristics of 283 STEMI patients who had IMR measured at the end of emergency PCI
CharacteristicsA All patients IMR P value
Lowest tertile ≤17 Mid-tertile 17 to ≤34.9 Upper tertile >34.9
n = 283 n = 95 n = 94 n = 94
Age (yr) 59 (12) 59 (11) 58 (12) 62 (12) 0.057
Male sex, n (%) 206 (73) 66 (70) 70 (74) 72 (75) 0.663
BMI (kg/m2) 29 (5) 29 (5) 30 (5) 28 (5) 0.066
Medical history
   Hypertension, n (%) 91 (32) 36 (38) 21 (22) 35 (36) 0.042
   Currently smoking, n (%) 175 (62) 64 (67) 57 (61) 54 (57) 0.360
   Hypercholesterolemia, n (%) 78 (28) 29 (30) 23 (24) 26 (28) 0.638
   Diabetes mellitusB, n (%) 30 (11) 12 (13) 6 (6) 12 (13) 0.278
   Previous angina, n (%) 32 (11) 4 (4) 15 (16) 13 (14) 0.016
   Previous myocardial infarction, n (%) 20 (7) 6 (6) 9 (10) 5 (5) 0.545
   Previous PCI, n (%) 14 (5) 2 (2) 6 (6) 6 (6) 0.295
Presenting characteristics
   Heart rate, bpm 78 (17) 77 (17) 76 (16) 80 (17) 0.203
   Systolic blood pressure, mmHg 136 (24) 136 (26) 134 (25) 137 (23) 0.767
   Diastolic blood pressure, mmHg 79 (14) 77 (14) 80 (15) 81 (13) 0.099
   Time from symptom onset to reperfusion, min 174 (120, 316) 157 (114, 267) 175 (120, 288) 203 (130, 402) 0.112
   Ventricular fibrillationC, n (%) 19 (7) 4 (4) 7 (7) 8 (8) 0.486
   Heart failure, Killip class at presentation, n (%)      I 201 (71%) 77 (81%) 70 (75%) 54 (57%)
                                                                                                     II 62 (22%) 18 (19%) 18 (19%) 26 (28%) <0.001
                                                                                                     III/IV 20 (7) 0 (0) 6 (6) 14 (15)
ST-segment elevation resolution post-PCI, n (%)
   <50% 78 (28) 8 (9) 31 (33) 39 (41) <0.001
   ≥50% 204 (72) 86 (91) 63 (67) 55 (59)
Reperfusion strategy, n (%)
   Primary PCI 262 (93) 89 (94) 87 (93) 86 (92)
   Rescue PCI (failed thrombolysis) 14 (5) 4 (4) 4 (4) 6 (6) 0.929
   Successful thrombolysis (convalescent STEMI) 7 (3) 2 (2) 3 (3) 2 (2)
Coronary angiography
   Number of diseased arteriesD, n (%)                            1 158 (56) 55 (58) 51 (54) 52 (55)
                                                                                                     2 83 (29) 27 (28) 28 (30) 28 (30) 0.963
                                                                                                     3 37 (13) 12 (13) 12 (13) 13 (14)
   Culprit artery, n (%)                                                           LM 5 (2) 1 (1) 3 (3) 1 (1)
                                                                                                     LAD 107 (38) 32 (34) 36 (38) 39 (42)
                                                                                                     LCX 51 (18) 18 (19) 17 (18) 16 (17) 0.870
                                                                                                     RCA 125 (44) 45 (47) 41 (44) 39 (42)
   TIMI coronary flow grade pre-PCI, n (%)                     0/1 204 (72) 58 (61) 70 (74) 76 (81)
                                                                                                     2/3 79 (30) 37 (39) 24 (26) 18 (19) 0.008
   TIMI coronary flow grade post-PCI, n (%)                   0/1 2 (1) 1 (1) 0 (0) 1 (1)
                                                                                                     2/3 281 (99) 94 (99) 94 (100) 93 (99) 1.000
   TIMI frame count pre-PCI 29 (18, 44) 33 (18, 43) 24 (18, 35) 36 (25, 52) 0.216
   TIMI frame count post-PCI 15 (10, 25) 12 (8, 19) 14 (10, 23) 21 (14, 30) <0.001
   TIMI blush grade post-PCI                                               0/1 71 (26.4) 18 (19.6) 20 (22.7) 33 (37.1) 0.021
                                                                                                     2/3 198 (73.6) 74 (80.4) 68 (77.3) 56 (62.9)
   Culprit lesion, percentage residual stenosis 12.4 (5.5) 11.9 (5.9) 12.6 (5.6) 12.7 (5.2) 0.541
   Coronary flow reserve 1.8 (0.9) 1.9 (1.1) 1.9 (0.8) 1.5 (0.6) <0.001
   IMR 24 (15, 44) 12 (10, 15) 24 (21, 29) 53 (44, 75) <0.001
   Fractional flow reserve 0.90 (0.10) 0.89 (0.08) 0.91 (0.10) 0.94 (0.06) <0.001
Treatment in the catheter laboratory
   Aspiration thrombectomy, n (%) 203 (71.7) 66 (69.5) 67 (71.3) 70 (74.5) 0.752
   Glycoprotein IIbIIIa inhibitor 259 (91.5) 87 (91.6) 85 (90.4) 87 (92.6) 0.898
Killip classification of heart failure after acute myocardial infarction: class I, no heart failure; class II, pulmonary rales or crepitations, a third heart sound, and elevated 
jugular venous pressure; class III, acute pulmonary edema; class IV, cardiogenic shock. AData are reported as mean (SD), median (interquartile range [IQR]), or N (%) as 
appropriate. P values have been obtained from a 1-way ANOVA or Fisher test. TIMI flow grades pre- and post-PCI were grouped as 0/1 versus 2/3 for this analysis. BDiabetes 
mellitus was defined as a history of diet-controlled or treated diabetes. CSuccessfully electrically cardioverted ventricular fibrillation at presentation or during emergency PCI 
procedure. DMultivessel coronary artery disease was defined according to the number of stenoses of at least 50% of the reference vessel diameter, by visual assessment, 
and whether there was left main stem involvement. The blood results on admission and their changes during the first 2 days after admission are described in Supplemental 
Table 1. Missing data: NT-BNP and IL-6 results were available in 121 (42.8%) subjects on the first day after STEMI and in 151 (53.4%) subjects at 6 months. STEMI, 
ST-elevation myocardial infarction; IMR, index of microvascular resistance (mmHg × s or units); PCI, percutaneous coronary intervention; LAD, left anterior descending 
coronary artery; LCX, left circumflex coronary artery; LM, left main coronary artery; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.
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predictors of  (a) all-cause death and heart failure events and (b) MACE. The assumption of  proportional 
hazards was assessed using Schoenfield residuals. All statistical analyses were carried out using R v 2.15.1 
or later. A P value of  greater than 0.05 indicates the absence of  evidence for a statistically significant effect.
Results
Patient characteristics and culprit CFR and IMR following coronary reperfusion. 283 STEMI patients had IMR 
(Table 1 and Supplemental Table 1; supplemental material available online with this article; doi:10.1172/jci.
insight.85768DS1) and CFR (Supplemental Table 2) measured in the culprit coronary artery without compli-
cation at the end of  emergency PCI followed by cardiac MRI 2.1 ± 1.8 days later. Case examples are shown in 
Figure 1. 264 (93%) patients had a second MRI scan to assess LV outcomes 6 months later (Figure 2).
The median IMR and CFR were 25 and 1.6, respectively, with IQRs of  15–48 and 1.1–2.1. An increased 
IMR (an IMR > median), a reduced CFR (a CFR < median), or both occurred in 136 (48%), 205 (72%), 
and 107 (38%) patients, respectively.
Myocardial hemorrhage and microvascular obstruction disclosed by cardiac MRI 2 days after reperfusion. The 
MRI findings are described in Table 2 and Supplemental Table 3, respectively. Intraobserver and interob-
server reliability for myocardial hemorrhage is described in the Supplemental Results.
213 (97%) patients had T2*-MRI maps and IMR and CFR measurements (Table 3). Myocardial hem-
orrhage and microvascular obstruction occurred in 89 (42%) and 114 (54%) patients 2 days after reperfu-
sion, respectively.
Relationships between IMR after reperfusion and incident infarct pathologies 2 days later. IMR was higher in 
patients with myocardial hemorrhage (median [IQR], 37 [21–63]) than in patients without myocardial 
hemorrhage (median [IQR], 17 [12–33]), including those patients that had microvascular obstruction in 
Figure 1. Three patients with acute ST-elevation myocardial infarction treated by primary percutaneous coronary intervention and with the same 
antithrombotic therapies, including aspirin, clopidogrel, heparin, and glycoprotein IIbIIIa inhibitor therapy with tirofiban. Each patient had successful 
primary percutaneous coronary intervention (PCI), as evidenced by normal thrombolysis in myocardial infarction (TIMI) flow grade 3 the end of the pro-
cedure. Cardiac MRI was performed for each patient 2 days later. Coronary artery function was measured in 283 patients, of whom 281 (99%) had cardiac 
MRI and 213 (75%) had T2* MRI for assessment of myocardial hemorrhage. Top: A patient with normal index of microvascular resistance (IMR <25), normal 
coronary flow reserve (CFR >2.0), and no evidence of microvascular injury on MRI. A diagnostic guide wire study of microvascular function in the terri-
tory of the culprit coronary artery immediately after primary PCI. IMR and CFR measurements were derived from coronary thermodilution. Microvascular 
function was normal (IMR 12, CFR 2.6), indicating successful myocardial reperfusion. Two days later, MRI ruled out myocardial hemorrhage (middle right 
image) or microvascular obstruction (right). Middle: A patient with normal IMR, low CFR, and microvascular obstruction but no hemorrhage on MRI 2 days 
later. The diagnostic guide wire study of culprit artery microvascular function at the end of primary PCI indicated an abnormal CFR (0.9) but a preserved 
IMR (11). Late gadolinium contrast-enhanced MRI revealed microvascular obstruction (right image, blue arrow). Bottom: A patient with high IMR, low 
CFR, and hemorrhagic infarction on MRI. The diagnostic guide wire study of culprit microvascular function immediately after primary PCI indicated severe 
microcirculatory dysfunction (IMR 89, CFR 1.0). T2*-MRI (middle right image) revealed myocardial hemorrhage (red arrow) within the infarct core. Contrast-
enhanced MRI revealed microvascular obstruction (right image, red arrow) within the bright area of infarction. The microvascular obstruction within the 
infarct core spatially corresponded with the myocardial hemorrhage.
Downloaded from http://insight.jci.org on May 12, 2016.   http://dx.doi.org/10.1172/jci.insight.85768
5insight.jci.org   doi:10.1172/jci.insight.85768
c l i n i c a l  m e d i c i n e
the absence of  myocardial hemorrhage (median [IQR], 17 [13–39]; P < 0.001) (Figure 3 and Supplemental 
Table 3). IMR was more strongly associated with myocardial hemorrhage (odds ratio [95% CI], 4.24 [2.38, 
7.58]; P < 0.001) than with microvascular obstruction (odds ratio [95% CI], 2.84 (1.70, 4.73); P < 0.001).
The optimal cut-offs for IMR in predicting myocardial hemorrhage and microvascular obstruction are 
summarized in Supplemental Table 4. Considering myocardial hemorrhage, an IMR >27 had a negative 
predictive value of  0.74 (0.65, 0.82).
Relationships between CFR after reperfusion and incident microvascular pathology 2 days later. CFR was lower 
in patients with myocardial hemorrhage (odds ratio [95% CI], 1.4 [1.0–1.8]) compared with patients with-
out myocardial hemorrhage (1.7 [1.4–2.5]), including the subset of  patients that had microvascular obstruc-
tion in the absence of  myocardial hemorrhage (1.5 [1.1–1.8]) (P < 0.001) (Figure 3).
Relationships between ECG evidence of  failed myocardial reperfusion and incident microvascular pathology 2 days 
later. Seventy-eight (28%) patients had persistent ST-segment elevation defined as <50% resolution from 
Figure 2. CONSORT flow diagram of the cohort study. STEMI, ST-elevation myocardial infarction; CMR, cardiac magnetic resonance; CFR, coronary flow 
reserve; IMR, index of microvascular resistance.
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the prereperfusion ECG 60 minutes after reperfusion. Of  these patients, myocardial hemorrhage occurred 
in 38 (sensitivity 0.61, specificity 0.66, positive predictive value 0.43, negative predictive value 0.80) and 
microvascular obstruction occurred in 54 (sensitivity 0.69, specificity 0.57, positive predictive value 0.38, 
negative predictive value 0.83).
Forty (14%) patients had persistent ST-segment elevation defined as <30% resolution from the pre-
reperfusion ECG 60 minutes after reperfusion. Of  these patients, myocardial hemorrhage occurred in 17 
(sensitivity 0.19, specificity 0.89, positive predictive value 0.55, negative predictive value 0.60) and micro-
vascular obstruction occurred in 26 (sensitivity 0.18, specificity 0.90, positive predictive value 0.65, negative 
predictive value 0.52).
Multivariable associations among IMR, CFR and microvascular pathologies. IMR (Tables 4 and 5) and CFR 
(Supplemental Tables 5 and 6) were multivariable associates of  microvascular obstruction and myocardial 
hemorrhage, respectively.
Associations of  IMR and CFR after reperfusion with the circulating acute-phase response. Blood samples 
had been collected in the subset of  STEMI patients who had been enrolled during office hours. IL-6, 
which is an immune cytokine that reflects endothelial activation, was measured in 121 and 151 patients 
1 day and 6 months after STEMI, respectively. The clinical characteristics of  these patients, and the 
associations with IMR and CFR, were similar to those of  the main study population (Supplemental 
Tables 7 and 8).
IMR was positively associated with IL-6. The IMR values in groups of  patients categorized by tertiles 
of  IL-6 concentration at baseline were 19 (IQR, 15–34) versus 23 (IQR, 16–34) versus 30 (IQR, 20–60) (P 
= 0.008). IMR was associated with log IL-6 at baseline (regression coefficient [95% CI], 0.07 [0.04, 0.10]; 
P < 0.001] and the within-subject change in log IL-6 at 6 months from baseline (regression coefficient [95% 
CI], 0.23 [0.0, 0.10]; P < 0.001).
CFR measured acutely was inversely associated with IL-6 concentration on day 1. The CFR values in 
groups of  patients categorized by tertiles of  IL-6 (<5.4 pg/ml vs. 5.4 to ≤8.9 pg/ml vs. >8.9 pg/ml) were 
Table 2. Left ventricular function, volumes, and pathology in 281 STEMI patients categorized according to tertile of IMR  
measured at the end of emergency PCI followed by contrast-enhanced MRI
Characteristics All patients IMR ≤17 17 < IMR ≤ 34.9 IMR >34.9 P value
n = 281 n = 95 n = 92A n = 94
MRI findings 2 days post-MI
 LV ejection fraction, % 55 (10) 59 (9) 55 (9) 52 (10) <0.001
 LV end-diastolic volume, ml
  Men 160 (32) 157 (35) 159 (30) 164 (32) 0.381
  Women 124 (25) 125 (22) 129 (25) 118 (27) 0.355
 LV end-systolic volume, ml
  Men 74 (54, 92) 62 (50, 81) 74 (55, 91) 77 (65, 103) 0.006
  Women 53 (41, 67) 45 (40, 60) 58 (42, 71) 60 (46, 67) 0.121
Edema and infarct characteristics
 Extent of myocardial edema, % LV mass 32 (12) 28 (10) 31 (12) 36 (12) <0.001
 Infarct size, % LV mass 16 (7, 27) 10 (3, 19) 17 (5, 28) 24 (13, 33) <0.001
 Late microvascular obstruction, n (%) 142 (50) 30 (32) 48 (51) 64 (68) <0.001
 Late microvascular obstruction, % LV mass 0.1 (0.0, 3.5) 0.0 (0.0, 0.8) 0.3 (0.0, 2.9) 2.1 (0.0, 7.8) <0.001
MRI findings 6 months post-MI (n = 259)
 LV ejection fraction at 6 months, % 63 (57, 70) 66 (63, 71) 62 (56, 68) 59 (52, 65) <0.001
 Change in LV end-diastolic volume  
 at 6 months from baseline, ml
  Men 6.3 (–7.9, 20.6) –0.4 (–16.6, 10.2) 8.2 (–5.1, 20.1) 12.6 (–5.1, 29.9) <0.001
  Women 0.9 (–11.4, 9.9) –4.3 (–11.4, 5.0) 6.6 (–4.0, 12.9) 2.3 (–14.1,17.3) 0.232
Area at risk was measured with T2-mapping. Data are given as n (%) or mean (SD). P values were obtained using 1-way ANOVA, Kruskal-Wallis test, or 
a Fisher test. AData are reported as mean (SD), median (IQR), or n (%) as appropriate. MRI data were not available in 2 patients. STEMI, ST-elevation 
myocardial infarction; IMR, index of microvascular resistance; PCI, percutaneous coronary intervention; LV, left ventricle; T1, myocardial longitudinal 
relaxation time.
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1.6 (IQR, 1.3, 2.2) versus 1.5 (IQR, 1.2, 2.1) versus 1.2 (IQR, 1.0, 1.7), respectively (P = 0.028). CFR was 
not associated with log IL-6 at baseline or the within-subject change in IL-6 (data not shown).
In order to investigate the relationships between IMR and IL-6 and the severity of  microvascular 
pathology, as revealed by cardiac MRI, patients were categorized for the occurrence of  microvascular 
obstruction or myocardial hemorrhage. In patients with myocardial hemorrhage (n = 41), IMR was 
associated with the natural log of  IL-6 concentration at baseline (regression coefficient [95% CI], 0.11 
[0.06, 0.16]; P < 0.001) and the within-subject change in log IL-6 at 6 months from baseline (n = 25) 
(regression coefficient [95% CI], –2.94 [–5.01, –0.87]; P = 0.008), whereas no associations were observed 
in patients without myocardial hemorrhage (n = 59), including in the subgroup of  patients (n = 9) with 
microvascular obstruction.
Associations for IMR and CFR with NT-proBNP, a biochemical measure of  LV remodeling. NT-proBNP results 
were available in 121 patients at baseline (index admission) and 152 patients at 6-month follow-up. IMR 
was associated with NT-proBNP at baseline (regression coefficient [95% CI] 9.2 [4.07, 21.3]; P = 0.004), 
independent of  LV end-diastolic volume at baseline (P = 0.006), whereas CFR was not (P = 0.726).
Both IMR and CFR were associated with NT-proBNP at 6 months after adjustment for LV ejection 
fraction and LV end-diastolic volume at baseline (coefficient [95% CI], 3.39 [0.91, 5.86]; P = 0.008 and 
–111.79 [–195.03, –28.55]; P = 0.009, respectively).
Figure 3. An index of microvascular resistance and coronary flow reserve according to the presence or absence of myocardial hemorrhage and microvas-
cular obstruction. Top: An index of microvascular resistance (IMR) and coronary flow reserve (CFR) according to the presence (n = 89 [42%]) or absence (n 
= 124 [58%]) of myocardial hemorrhage in 213 participants who had T2* mapping with MRI 2 days after reperfusion. IMR was higher and CFR was lower in 
patients with myocardial hemorrhage (T2*MRI positive) compared to that in patients without myocardial hemorrhage (T2* MRI negative). Bottom: IMR 
and CFR according to the presence (n = 25) or absence of microvascular obstruction (n = 99) in the subset of patients from above without myocardial hem-
orrhage (n = 124 [58%]). In this subset of patients with less severe vascular injury, IMR was similar in patients with or without microvascular obstruction 
(MVO), as revealed by contrast-enhanced MRI. By contrast, CFR was lower in patients with MVO compared to CFR in patients without MVO. Mann-Whit-
ney tests were used for the statistical analysis. In box-and-whisker plots, horizontal bars indicate the medians, boxes indicate 25th to 75th percentiles, 
and whiskers indicate 10th and 90th percentiles.
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Multivariable associations for IMR and CFR after reperfusion with LV remodeling at 6 months. IMR was a 
multivariable associate of  changes in LV end-diastolic volume from baseline after adjustment for initial 
LV end-diastolic volume and clinical characteristics (regression coefficient [95% CI] 0.13 [0.01, 0.24]; P = 
0.036; Supplemental Table 9), whereas CFR was not (P = 0.160).
Multivariable associations for IMR and CFR after reperfusion with LV ejection fraction at 6 months. IMR and CFR 
were multivariable associates of  the changes in LV ejection fraction from baseline (Supplemental Table 10).
Multivariable associations for IMR and CFR adverse health outcomes in the longer term. All patients (n = 283) 
had long-term follow-up data completed. The median duration of  follow-up was of  845 days (after discharge 
censor duration range, 598–1,098 days). Thirty (11%) patients died or experienced a first heart failure event 
during the index hospitalization or after discharge. These events included 5 cardiovascular deaths, 3 noncar-
diovascular deaths, and 22 episodes of  heart failure (Killip class 3 or 4 heart failure [n = 20] or cardiac device 
implantation [n = 2 received a defibrillator]). Thirteen (4.5%) patients died or experienced a first heart failure 
hospitalization after discharge, and 8 (61.5%) of  these patients had an elevated IMR at baseline.
IMR (per 5-unit difference) was a univariable (hazard ratio [95% CI], 1.08 [1.04, 1.12]; P < 0.001) and 
multivariable (hazard ratio [95% CI], 1.09 [1.04, 1.144]; P < 0.001) associate of  all-cause death or heart 
failure hospitalization (Table 6). For a 10-unit difference in IMR, the multivariable hazard ratio for this 
outcome was 1.18 ([95% CI] 1.09, 1.26) (P < 0.001). An IMR >40 was associated with all-cause death or 
heart failure (4.36 [95% CI], 2.09, 9.06; P < 0.001). CFR was not a univariable associate of  all-cause death 
or heart failure hospitalization (CFR, P = 0.124).
Forty (14%) patients died or experienced a MACE during the index hospitalization or after discharge. IMR 
(per 5-unit difference) was a univariable (hazard ratio [95% CI], 1.08 [1.04, 1.11]; P < 0.001) and multivariable 
(hazard ratio [95% CI], 1.07 [1.03, 1.11]; P < 0.001) associate of MACE, whereas CFR was not (Table 6).
Discussion
The main findings of  our study are that (a) IMR and CFR can be routinely measured in the culprit 
coronary artery at the end of  emergency PCI; (b) IMR and CFR were both associated with microvas-
cular obstruction and myocardial hemorrhage; (c) compared with IMR, CFR was discriminative of  
microvascular obstruction in patients with less severe myocardial injury, as reflected by the absence of  
myocardial hemorrhage, whereas IMR was not discriminative in this group (Figure 3); (d) compared 
with CFR, IMR was more closely associated with severe vascular damage, as reflected by myocardial 
hemorrhage, persistent ST-segment elevation, and Killip heart failure classification (Tables 5 and 7); (e) 
IMR and CFR were associated with proinflammatory cytokines, as revealed by associations with log 
Table 3. Coronary angiographic findings and physiological characteristics of 213 STEMI patients who had CFR and IMR  
measured at the end of emergency PCI followed by MRI with evaluable T2* mapping of myocardial hemorrhage
Characteristics All patients MVO and myocardial hemorrhage status P value
MVO –, IMH – MVO +, IMH – MVO +, IMH +
n = 213 n = 99 n = 25 n = 89
Culprit artery, n (%) LAD 85 (40) 36 (36) 8 (32) 41 (46)
LCX 43 (20) 15 (15) 4 (16) 24 (27) 0.02
RCA 85 (40) 48 (48) 13 (52) 24 (27)
TIMI coronary flow grade pre-PCI, n (%) 0/1 154 (72) 58 (59) 19 (76) 77 (86)
2/3 59 (28) 41 (41) 6 (24) 12 (14) <0.001
TIMI coronary flow grade post-PCI, n (%) 0/1 1 (0.5) 0 (0) 0 (0) 1 (1)
2/3 212 (99) 99 (100) 25 (100) 88 (99) 0.535
CFR 1.8 (0.9) 2.0 (1.1) 1.6 (0.5) 1.5 (0.7) 0.001
IMR 25 (15, 47) 19 (12, 34) 15 (11, 34) 36 (21, 61) <0.001
Fractional flow reserve 0.90 (0.10) 0.91 (0.08) 0.91 (0.06) 0.92 (0.10) <0.001
The patients are categorized according to the presence or absence of myocardial hemorrhage and MVO, as revealed by MRI 2 days after reperfusion. STEMI, 
ST-elevation myocardial infarction; CFR, coronary flow reserve; IMR, index of microvascular resistance; PCI, percutaneous coronary intervention; MVO, 
microvascular obstruction; IMH, intramyocardial hemorrhage; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right 
coronary artery; TIMI, thrombolysis in myocardial infarction.
Downloaded from http://insight.jci.org on May 12, 2016.   http://dx.doi.org/10.1172/jci.insight.85768
9insight.jci.org   doi:10.1172/jci.insight.85768
c l i n i c a l  m e d i c i n e
IL-6 and NT-proBNP; (f) IMR was associated with changes in LV volume at 6 months, whereas CFR 
was not; (g) IMR was a multivariable associate of  adverse health outcome events during longer-term 
follow-up, whereas CFR was not; and (h) compared with persistent ST-segment elevation >50% on the 
ECG after reperfusion, an increased IMR had similar predictive value for infarct pathologies (IMR >27) 
and health outcomes (IMR >40), unlike the duration of  symptoms, CFR, and the angiogram.
In line with our hypotheses, IMR and CFR measured in the culprit artery at the end of  PCI were mul-
tivariable associates of  microvascular pathology; however, differences between IMR and CFR were also 
observed. CFR was discriminative of  microvascular function in patients with less severe vascular injury 
(Figure 3), whereas IMR was not, implying that CFR is more closely associated with reversible microvascu-
lar injury. Unlike IMR, CFR was not associated with LV remodeling. These results potentially explain the 
lack of  association between CFR and adverse health outcomes.
The threshold for IMR and outcome has varied between studies (22–24, 28, 29). In our analysis 
the IMR cut-offs for infarct pathologies and adverse health outcomes differed slightly. An IMR of  
27 was most closely associated with microvascular obstruction and myocardial hemorrhage, whereas 
a higher IMR of  40 was most closely associated with all-cause death or heart failure. We think that 
the higher IMR cut-off  for the occurrence of  adverse health outcomes reflects the pathophysiological 
consequences of  infarct pathologies, and so the higher cut-off  for clinical outcomes intuitively makes 
sense. Our paper adds to the literature on IMR in patients with acute STEMI (22–24, 28, 29) and pro-
vides pathophysiologic and clinical data in support of  the validity of  IMR as a direct invasive test of  
myocardial reperfusion (30).
The 12-lead surface ECG 60 to 90 minutes after reperfusion is the standard of  care diagnostic test for 
assessing the efficacy of  coronary reperfusion (1). Our results provide further pathophysiologic validation 
of  the ECG. However, ECG evidence of  failed myocardial reperfusion occurred in a minority of  patients 
(14% for <30% ST-segment resolution; 28% for <50% ST-segment resolution). Consequently, the surface 
ECG resulted in a missed diagnosis of  failed myocardial reperfusion in almost half  of  all comers in whom 
failed microvascular reperfusion had occurred, as revealed by cardiac MRI (reference test). In multivariate 
analysis of  the predictors of  all-cause death or heart failure, both IMR (for a 5-unit change) and <50%ST- 
Table 4. Multivariable associations between clinical characteristics at presentation, including IMR (for a 
5-unit difference in IMR) at the end of emergency PCI, and the occurrence of microvascular obstruction 
2 days later (n = 200) in patients with acute STEMIA
Binary logistic regression Odds ratio (95% CI) P value
IMR (for a 5-unit difference in IMR) 1.12 (1.05, 1.19) <0.001
Age, yr 1.00 (0.97, 1.03) 0.841
Male gender 1.82 (0.95, 3.48) 0.072
BMI 0.99 (0.93, 1.05) 0.641
Previous MI 0.73 (0.15, 3.59) 0.701
Diabetes mellitus 1.25 (0.49, 3.19) 0.646
Previous PCI 5.19 (0.79, 34.23) 0.087
Smoker 1.66 (0.85, 3.23) 0.136
Hypertension 1.42 (0.74, 2.76) 0.294
Hypercholesterolemia 0.69 (0.34, 1.41) 0.309
Previous angina 0.87 (0.33, 2.27) 0.777
Heart rate, bpm 0.99 (0.98, 1.01) 0.519
SBP per 10 mmHg 1.02 (0.90, 1.15) 0.789
Symptom to reperfusion time per 10 minutes 1.01 (1.00, 1.03) 0.077
TIMI blush grade post-PCI 2/3 1.50 (0.78, 2.90) 0.228
Culprit lesion, % residual stenosis 0.98 (0.92, 1.03) 0.362
ST-segment resolution <50% 2.37 (1.20, 4.69) 0.013
Harrel’s C-statistic 0.743
ATIMI frame count was excluded due to numerical instability. The Harrel’s C-statistic reflects the predictive power 
of the multivariable model. STEMI, ST-elevation myocardial infarction; IMR, index of microvascular resistance; PCI, 
percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.
Downloaded from http://insight.jci.org on May 12, 2016.   http://dx.doi.org/10.1172/jci.insight.85768
1 0insight.jci.org   doi:10.1172/jci.insight.85768
c l i n i c a l  m e d i c i n e
segment resolution were predictors of  this outcome (Table 6). The diagnostic and prognostic value of  
the ECG varied markedly between <30% ST-segment resolution and <50% ST-segment resolution. The 
specificity (rule-in test) and negative predictive values (rule-out test) for the different ECG cut-offs differed 
markedly, whereas the predictive values of  IMR for cut-offs 27 and 40 for all of  the outcomes were broadly 
similar. Usually, patients have returned to the ward by the time of  the 90-minute ECG, limiting the options 
for more intensive therapy. On the other hand, IMR is a direct, invasive test that can be used to assess the 
efficacy of  myocardial reperfusion.
TIMI coronary flow grades before but not after PCI were associated with IMR (Table 1) and micro-
vascular pathology (Table 3). Microvascular obstruction occurred in half  of  the study participants, despite 
successful restoration of  epicardial coronary artery flow in the majority (99% in our population, in line 
with previous reports; refs. 7–9). Furthermore, TIMI blush grades were not associated with microvascular 
pathology or adverse health outcomes in the longer term (Tables 4–7). TIMI blush grades require high-
quality angiography and expertise for reliable assessment. Blush grades have applications for research pur-
poses rather than in routine practice (1, 3).
Overall, IMR was more closely associated with severe irreversible infarct pathology, i.e., myocardial 
hemorrhage and subsequent adverse LV and clinical outcomes, than other tests of  myocardial reperfu-
sion. In clinical practice involving patients with acute STEMI, microvascular obstruction and myocardial 
hemorrhage routinely pass undetected, despite having proven prognostic value. We think that IMR has 
potential to address this disparity in diagnosis. The high negative predictive value of  an IMR >27 for myo-
cardial hemorrhage points to its potential value as an early rule-out test for failed myocardial reperfusion. 
On the other hand, we do not propose IMR as an alternative for CMR, which is performed subsequently 
downstream in the care pathway as a test for LV function, pathology, and viability (1, 3).
In STEMI patients with less severe vascular injury, as revealed by the absence of  myocardial hemor-
rhage, CFR was associated with microvascular obstruction, which is a potentially reversible pathology (6, 
31). This observation is consistent with the notion that CFR reflects coronary artery function and vasore-
activity. However, CFR was not associated with LV remodeling or adverse health outcomes in the longer 
term, limiting its clinical utility. By contrast, IMR, which is a quantitative parameter of  microvascular 
Table 5. Multivariable associations between clinical characteristics at presentation, including IMR  
(for a 5-unit difference in IMR) at the end of emergency PCI, and the occurrence of myocardial 
hemorrhage 2 days later (n = 200) in patients with acute STEMIA
Binary logistic regression Odds ratio (95% CI) P value
IMR (5-unit difference in IMR) 1.11 (1.04, 1.19) 0.003
Age, yr 1.02 (0.98, 1.06) 0.277
Male gender 2.73 (1.17, 6.38) 0.020
BMI 0.99 (0.92, 1.08) 0.892
Previous MI 0.89 (0.15, 5.19) 0.893
Diabetes mellitus 1.48 (0.49, 4.44) 0.485
Previous PCI 4.26 (0.57, 31.87) 0.158
Smoker 3.78 (1.61, 8.85) 0.002
Hypertension 1.44 (0.65, 3.16) 0.367
Hypercholesterolemia 1.16 (0.48, 2.82) 0.736
Previous angina 0.81 (0.25, 2.60) 0.717
Heart rate (bpm) 1.00 (0.98, 1.02) 0.997
SBP per 10 mmHg 0.98 (0.85, 1.14) 0.825
Symptom to reperfusion time per 10 minutes 1.00 (0.99, 1.02) 0.621
TIMI blush grade post-PCI 2/3 1.31 (0.62, 2.77) 0.483
Culprit lesion, % residual stenosis 1.01 (0.95, 1.07) 0.823
ST-segment resolution <50% 2.29 (1.03, 5.10) 0.043
Harrel’s C-statistic 0.766
ATIMI frame count was excluded due to numerical instability. The Harrel’s C-statistic reflects the predictive power 
of the multivariable model. STEMI, ST-elevation myocardial infarction; IMR, index of microvascular resistance; PCI, 
percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.
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resistance, was associated with IL-6 concentrations, notably in the subgroup of  patients with myocardial 
hemorrhage. The association between IMR and IL-6 provides a mechanistic explanation. In the setting of  
acute reperfused STEMI, an elevated IMR measured in the culprit coronary artery after reperfusion reflects 
severe microvascular dysfunction. The association between IMR and subsequent systemic concentrations 
of  IL-6 on the first day after STEMI reflects systemic inflammation and vascular injury, reflected by the 
occurrence of  myocardial hemorrhage within the infarct core. These pathophysiologic insights potentially 
explain the strong associations between IMR measured acutely and surrogate outcomes, including adverse 
LV remodeling, and all-cause death and heart failure early after STEMI.
Our study adds to previous investigations of  IMR and CFR in patients with acute STEMI. Van de 
Hoef  et al. (32) found that, in 148 STEMI survivors, a CFR <2.0 measured in the culprit coronary artery 
was associated with MACE over 10 years after STEMI. The prognostic significance of  IMR in patients 
with acute STEMI is more established. IMR is independently associated with LV function (33), infarct 
pathology (24, 28), and health outcomes after STEMI (23). In a pooled analysis of  253 patients with acute 
STEMI followed for a median of  2.8 years, Fearon et al. (23) found that an IMR >40 was a multivariable 
associate of  all-cause death and heart failure, whereas CFR was not. Other comparative studies of  CFR 
and IMR are limited by sample size (n = 27–45) (22, 29, 33, 34) and follow-up duration (3–6 months) (22, 
29, 33, 34). Taken together, our study adds importantly to what is already known. We describe the larg-
est study to date involving invasive measurements of  microvascular resistance in the culprit artery, infarct 
characterization using cardiac MRI 2 days and 6 months later, and longitudinal follow-up for surrogate 
outcomes and all-cause death or heart failure events during longer-term follow-up.
Cuculi et al. recently reported that CFR and IMR are modifiable (22). They found that the change 
in CFR within 24 hours of  reperfusion is associated with infarct size and myocardial salvage, which is 
consistent with previous observations and those in our study (24, 28, 33). Further studies are warranted 
to determine whether IMR (with or without CFR) might be a clinically useful biomarker to risk-stratify 
Table 6. Relationships of IMR and CFR and MACE during or after the index hospitalization  
(median duration of follow-up was of 845 days [after discharge censor duration range, 598–1,098 days])
Associations Hazard ratio (95% CI) P value
Univariable associations
  IMR (for a 5-unit change) 1.08 (1.04, 1.11) <0.001
  CFR (for a 0.2-unit change) 0.95 (0.87, 1.03) 0.225
  CFR (for a 0.5-unit change) 0.27 (0.03, 2.25) 0.225
Multivariable associations
 Model A
  IMR (for a 5-unit change) 1.07 (1.03, 1.11) <0.001
  Hypertension 1.72 (0.88, 3.36) 0.113
  TIMI blush grade 2/3 1.22 (0.56, 2.68) 0.613
 Model B
  IMR (for a 5-unit change) 1.06 (1.02, 1.10) 0.001
  Hypertension 1.83 (0.98, 3.44) 0.059
  ST-segment resolution <50% 3.45 (1.80, 6.62) <0.001
 Model C
  CFR (for a 0.5-unit change) 0.10 (0.00, 2.14) 0.142
  Hypertension 2.37 (1.09, 5.14) 0.029
  TIMI blush grade 2/3 0.55 (0.25, 1.22) 0.140
 Model D
  CFR (for a 0.5-unit change) 0.52 (0.06, 4.48) 0.555
  Hypertension 1.76 (0.93, 3.22) 0.787
  ST-segment resolution <50% 4.00 (2.10, 7.64) <0.001
Forty (14%) patients died or experienced a MACE during the index hospitalization or after discharge. IMR, index of 
microvascular resistance; CFR, coronary flow reserve; MACE, major adverse cardiac events; TIMI, thrombolysis in 
myocardial infarction.
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patients for targeted therapy, since practice guidelines identify failed myocardial reperfusion as a clinical 
problem of  unmet need (1).
The study population included 21 patients initially treated with thrombolysis, and 14 of  these patients 
had rescue PCI. The main results of  our study were unchanged when these patients were removed (data not 
shown), and myocardial hemorrhage was similar in patients treated by primary PCI versus thrombolysis. 
We conclude that guide wire–based assessment of  coronary microvascular function is of  diagnostic value 
in patients treated with thrombolysis.
Limitations. We performed a single-center natural history study involving prospective enrollment of  
patients with acute STEMI. We did not enroll consecutive patients (Figure 2). Coronary venous blood samples 
were not collected based on safety and logistics. Invasive assessments of  culprit artery microvascular function 
and contrast-enhanced MRI were obtained in 283 patients (n = 281 with both CFR and IMR); however, eval-
uable T2*maps were not evaluable in all of  these subjects due to cardiorespiratory motion and breath-holding 
problems in acutely ill patients. Enrollment in our study took place 24/7; however, blood sample handling for 
NT-proBNP and IL-6 was not feasible outside of  collection hours. The clinical characteristics of  the patients 
in whom blood samples were obtained were similar to the whole population (Supplemental Results).
The limited number of  adverse events constrained the number of  variables and statistical power in the 
Cox models. Our study builds on previous investigations in smaller patient cohorts. Although our study 
does not include a validation cohort, the prognostic importance of  IMR is consistent with previous studies 
involving IMR in STEMI patients (23). Our analysis does not permit inference on causality, and further 
studies are warranted.
Conclusions. Our results support the feasibility and pathophysiological validity of  IMR, over CFR and 
the ECG, as a routine diagnostic test for failed myocardial reperfusion in patients with acute STEMI. Rou-
tine measurement of  IMR has potential clinical utility for immediate stratification of  patients with acute 
STEMI following coronary reperfusion, and further research is warranted.
Table 7. Relationships of IMR and CFR and all-cause death or first hospitalization for heart failure 
during or after the index hospitalization (median duration of follow-up was of 845 days  
[after discharge censor duration range, 598–1,098 days])
Associations Hazard ratio (95% CI) P value
Univariable associations
  IMR (for a 5-unit change) 1.08 (1.05, 1.12) <0.001
  CFR (for a 0.2-unit change) 0.92 (0.82, 1.02) 0.124
  CFR (for a 0.5-unit change) 0.12 (0.01, 1.79) 0.124
Multivariable associations
 Model A
  IMR (for a 5-unit change) 1.07 (1.02, 1.11) 0.006
  Hypertension 2.32 (1.06, 5.05) 0.034
  TIMI blush grade 2/3 0.79 (0.34, 1.85) 0.588
 Model B
  IMR (for a 5-unit change) 1.07 (1.03, 1.11) <0.001
  Hypertension 2.47 (1.20, 5.06) 0.014
  ST-segment resolution < 50% 2.58 (1.24, 5.34) 0.011
 Model C
  CFR (for a 0.5-unit change) 0.10 (0.00, 2.14) 0.142
  Hypertension 2.37 (1.09, 5.14) 0.029
  TIMI blush grade 2/3 0.55 (0.25, 1.22) 0.140
 Model D
  CFR (for a 0.5-unit change) 0.23 (0.01, 3.58) 0.292
  Hypertension 2.34 (1.14, 4.81) 0.021
  ST-segment resolution < 50% 2.91 (1.40, 6.03) 0.004
Thirty (10.4% of 288) patients experienced all-cause death or heart failure hospitalization after discharge. IMR, index of 
microvascular resistance; CFR, coronary flow reserve; TIMI, thrombolysis in myocardial infarction.
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Methods
Participants and interventions
We performed a prospective cohort study in a single regional cardiac center between July 14, 2011, and 
November 22, 2012. Two hundred and eighty-eight STEMI patients provided written informed consent to 
undergo a diagnostic guide wire–based assessment after reperfusion and then MRI 2 days and 6 months 
later as well as follow-up for health outcomes in the longer term. Blood samples were obtained in a 
subset of  patients during office hours (day 1 and 6 months after STEMI) for measurement of  IL-6 and 
NT-proBNP, a biochemical measure of  LV wall stress. Patients were eligible if  they had an indication for 
primary PCI or thrombolysis for acute STEMI due to a history of  symptoms consistent with acute myo-
cardial ischemia and with supporting changes on the ECG (i.e., ST-segment elevation or new left bundle-
branch block) (1). Exclusion criteria represented standard contraindications to contrast MRI, including 
a pacemaker and estimated glomerular filtration rate <30 ml/min/1.73 m2. Acute STEMI management 
followed contemporary guidelines (1, 3). Aspiration thrombectomy, direct stenting, antithrombotic drugs, 
and other therapies were administered according to clinical judgment (Supplemental Methods). The Clin-
icalTrials.gov identifier for this study is NCT02072850, and the study design conforms with CONSORT, 
STROBE, and TREND guidelines.
Measurement of IMR and CFR at the end of PCI
A pressure- and temperature-sensitive coronary guide wire (St. Jude Medical, Minnesota, USA) was 
used to measure IMR and CFR in the culprit coronary artery at the end of  primary or rescue PCI. The 
guide wire was calibrated outside the body, equalized with aortic pressure at the ostium of  the guide 
catheter, and then advanced to the distal third of  the culprit artery. CFR is defined as the mean transit 
time at rest divided by the mean transit time during hyperemia. IMR is defined as the distal coronary 
pressure multiplied by the mean transit time of  3 sequential manual bolus injections of  saline (3 ml) at 
room temperature during maximal coronary hyperemia, measured simultaneously (mmHg × s or units) 
(24, 28, 33).
Hyperemia was induced by 140 μ/kg/min of  i.v. adenosine preceded by a 2-ml intracoronary bolus of  
200 μg of  nitrate. The mean aortic and distal coronary pressures were recorded during maximal hyperemia. 
In our study, the repeatability of  CFR and IMR was assessed by duplicate measurements 5 minutes apart 
in a subset of  12 consecutive patients, in line with previous observations (28). We have previously observed 
that repeated IMR measurements obtained by 4 different operators in 12 STEMI patients were highly cor-
related (r = 0.99, P < 0.001), with a mean difference between IMR measurements of  0.01 (mean standard 
error 1.59 [95% CI −3.52 to 3.54], P = 0.48) (28).
Cardiac MRI acquisition
MRI was performed on a Siemens MAGNETOM Avanto 1.5-Tesla scanner with a 12-element phased 
array cardiac surface coil (35). The imaging protocol (5, 36) included cine MRI with steady-state free pre-
cession (SSFP), T2 mapping (37, 38), T2*-mapping, and delayed-enhancement phase-sensitive inversion-
recovery pulse sequences (39). The scan acquisitions were spatially coregistered and also included different 
slice orientations to enhance diagnostic confidence.
T2 maps were acquired in contiguous short-axis slices covering the whole ventricle, using an investiga-
tional prototype T2-prepared TrueFisp sequence (37, 38) (Supplemental Methods). The hypointense infarct 
core on T2 mapping reflects the combination of  microvascular obstruction and myocardial hemorrhage (4). 
Typical imaging parameters were as follows: bandwidth, approximately 947 Hz/pixel; flip angle, 70°; T2 
preparations, 0 ms, 24 ms, and 55 ms, respectively; matrix, 160 × 105 pixels; spatial resolution, 2.6 × 2.1 × 
8.0 mm; and slice thickness, 8 mm.
Myocardial hemorrhage was detected using an investigational prototype T2* map sequence acquired 
in 3 short-axis slices (basal, mid, and apical). Typical imaging parameters were as follows: bandwidth, 
approximately 814 (×8) Hz/pixel; flip angle, 18°; matrix, 256 × 115; spatial resolution, 2.6 × 1.6 × 10 mm; 
and slice thickness, 8 mm. This method became available for use after 25 patients had been enrolled.
Early gadolinium enhancement (EGE) imaging was acquired 1, 3, 5, and 7 minutes after contrast injec-
tion using a TrueFISP readout and a fixed inversion time of  440 ms. Late gadolinium enhancement images 
covering the entire LV were acquired 10 to 15 minutes after i.v. injection of  0.15 mmol/kg of  gadoter-
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ate meglumine (Gd2+-DOTA, Dotarem, Guerbet S.A.) using segmented phase-sensitive inversion recovery 
turbo fast low-angle shot sequence (39). Typical imaging parameters were as follows: matrix, 192 × 256; 
flip angle, 25°; TE, 3.36 ms; bandwidth, 130 Hz/pixel; echo spacing, 8.7 ms; and trigger pulse, 2. The voxel 
size was 1.8 × 1.3 × 8 mm3. Inversion times were individually adjusted to optimize nulling of  apparently 
normal myocardium (typical values, 200 to 300 ms).
Cardiac MRI analyses
The images were analyzed on a Siemens work station by observers with at least 3 years MRI experience 
(N. Ahmed, D. Carrick, I. Mordi, S.M.O. Rauhalammi). All of  the images were reviewed by an experi-
enced MRI cardiologist (C. Berry). LV dimensions, volumes, and ejection fractions were quantified using 
computer-assisted planimetry (syngo MR, Siemens Healthcare). The late gadolinium enhancement images 
were analyzed for infarct size and microvascular obstruction by observers (N. Ahmed, I. Mordi) who were 
blinded to all of  the other data. In healthy volunteers, the absence of  late gadolinium enhancement was 
determined qualitatively by visual assessment.
In STEMI patients, myocardial T2/T2* values were segmented spatially and regions of  interest were 
defined as (a) remote myocardium, (b) injured myocardium, and (c) infarct core. The regions of  interest 
were planimetered to include the entire area of  interest, with distinct margins of  separation from tissue 
interfaces to avoid partial volume averaging. The remote myocardium region of  interest was defined as 
myocardium 180° from the affected zone with no visible evidence of  infarction, edema, or wall motion 
abnormalities (assessed by inspecting corresponding contrast-enhanced T1-weighted, T2-weighted, and 
cine images, respectively). The infarct zone region of  interest was defined as myocardium with pixel values 
(T2) >2 SD from remote myocardium on T2-weighted MRI (37, 38). The hypointense infarct core was 
defined as an area in the center of  the infarct territory having a mean T2* value of  at least 2 SDs below the 
T2* value of  the periphery of  the area at risk (37, 38). The assessment of  T2* maps and adjudication (pres-
ent/absent) of  a hypointense core was performed independently by D. Carrick.
Infarct definition and size. The presence of  acute infarction was established based on abnormalities in cine 
wall motion, rest first-pass myocardial perfusion, and delayed-enhancement imaging in two imaging planes. 
In addition, supporting changes on the ECG and coronary angiogram were also required. Acute infarction 
was considered present only if  late gadolinium enhancement was confirmed on both the axial and long-axis 
acquisitions. The myocardial mass of  late gadolinium (grams) was quantified using computer-assisted pla-
nimetry, and the territory of  infarction was delineated using a signal intensity threshold of  >5 SDs above a 
remote reference region and expressed as a percentage of  total LV mass (40). Infarct regions with evidence of  
microvascular obstruction were included within the infarct area, and the extent of  microvascular LV ventric-
ular mass was also measured. The measurements of  infarct size were performed by I. Mordi and N. Ahmed.
Microvascular obstruction. Microvascular obstruction was defined as a dark zone on EGE imaging 1, 3, 5, and 
7 minutes after contrast injection that remained present within an area of large gadolinium enhancement at 15 
minutes. Identification of microvascular obstruction was performed independently by I. Mordi and N. Ahmed.
Extent of  myocardial edema. The extent of  myocardial edema representing the jeopardized area at risk 
was defined as LV myocardium with pixel values (T2) >2 SDs from remote myocardium (37, 38, 41–
44). In order to assess the area at risk, the epicardial and endocardial contours on the last corresponding 
T2-weighted raw image with an echo time of  55 ms were planimetered (37). Contours were then copied to 
the computed T2 map and corrected when necessary by consulting the SSFP cine images.
Myocardial hemorrhage. On the T2* maps, a region of  reduced signal intensity within the infarcted area 
with a T2* value of  <20 ms (45–48) was considered to confirm the presence of  myocardial hemorrhage.
ECG
A 12-lead ECG was obtained before coronary reperfusion and 60 minutes afterwards. The extent of  ST-
segment resolution on the ECG assessed 60 minutes after reperfusion compared to the baseline ECG before 
reperfusion (49) was expressed as successful ≥50% ST-segment resolution on the ECG 60 minutes after 
reperfusion or or a lack of  <50% ST-segment resolution. Additionally the ST-segment resolution was cat-
egorized as follows: complete (~70%), incomplete (30% to <70%), or none (<30%).
Biochemical and hematology measurements
Serial systemic blood samples were obtained immediately after reperfusion in the cardiac catheterization 
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laboratory and subsequently on the first day (0600–0700 hours) during the initial in-patient stay in the 
Coronary Care Unit.
CRP was measured in an NHS hospital biochemistry laboratory using a particle-enhanced immunotur-
bimetric assay method (Cobas C501, Roche) and the manufacturer’s calibrators and quality control mate-
rial, as a biochemical measure of  inflammation. The high-sensitivity CRP assay measurement range was 
0.1–250 mg/l. The expected CRP values in a healthy adult are <5 mg/l, and the reference range in our 
hospital is 0–10 mg/l. IL-6 was measured using a high-sensitivity ELISA (R&D Systems) (50). The limit 
of  detection was <0.1 pg/ml, and the intraassay CV was 9.1%. NT-proBNP was measured in a research 
laboratory using an electrochemiluminescence method (e411, Roche), and the manufacturer’s calibrators 
and quality control material. The limit of  detection for IL-6 and NT-proBNP is 6.5 pg/ml and 5 pg/ml, 
respectively. Long-term coefficient of  variations of  low and high controls are typically <5% and were all 
within the manufacturer’s range.
Prespecified health outcomes
We prespecified adverse health outcomes that are pathophysiologically linked with STEMI. The primary 
composite outcome was (1) all-cause death or first heart failure event following the initial hospitalization 
(Supplemental Methods).
Research staff  screened for events from enrollment by checking the medical records and by contacting 
patients and their primary and secondary care physicians as appropriate, with no loss to follow-up (Figure 
2). Each serious adverse event was reviewed by a cardiologist who was independent of  the research team 
and blinded to all of  the clinical and MRI data. The serious adverse events were defined according to 
standard guidelines (refs. 51, 52, and Supplemental Methods) and categorized as having occurred either 
during the index admission or after discharge. All study participants were followed up for a minimum of  
18 months after discharge. The median duration of  follow-up was 845 days (after discharge censor duration 
range, 598–1,098 days).
Blinding
The study participants were blinded to all of  the clinical assessments, including CFR, IMR, ECG, and MRI 
results. The observers who analyzed the surrogate outcomes and those who adjudicated the adverse clinical 
events were blinded to all of  the other clinical data.
Statistics
The sample size calculation is described in the Supplemental Methods. We estimated that at least 30 all-
cause death or heart failure events would occur based on a conservative estimate of  the event rate (10%–
12%) at 18 months.
Categorical variables are expressed as number and percentage of  patients. Most continuous variables 
followed a normal distribution and are therefore presented as means together with SD. Those variables 
that did not follow a normal distribution are presented as medians with IQR. Differences in continuous 
variables between groups were assessed by 2-tailed Student’s t test or ANOVA for continuous data with 
normal distribution; otherwise, the nonparametric Wilcoxon rank-sum test or Kruskal-Wallis test was used. 
Differences in categorical variables between groups were assessed using a χ2 test or Fisher’s test, as appro-
priate. Correlation analyses were performed using Pearson or Spearman tests, as indicated. Random effects 
models were used to compute interrater and intrarater reliability measures (intraclass correlation coefficient 
[ICC]) for the reliability of  CFR and IMR values measured independently by 2 observers in 12 randomly 
selected patients from the cohort. In addition, ICC was measured for the reliability of  infarct core T2* val-
ues measured independently by 2 observers in 20 randomly selected patients from the cohort.
Univariable and multivariable linear regression methods to identify associates of  CFR and IMR values 
for infarct pathology revealed by MRI (infarct size, EGE, late microvascular obstruction, and myocardial 
hemorrhage) and circulating cytokines (IL-6, NT-proBNP) are described in the Supplemental Methods.
Receiver operating curve, Kaplan-Meier, and Cox proportional hazards methods were used to identify 
potential clinical predictors of  all-cause death/heart failure events, including patient characteristics, MRI 
findings, and IMR/CFR.
All P values were 2 sided, and P > 0.05 indicates the absence of  a statistically significant effect. Statisti-
cal analyses were performed using R v 2.15.1 or SAS v 9.3 or higher versions of  these programs.
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